Current Report Filing (8-k)
04 April 2023 - 01:22AM
Edgar (US Regulatory)
0001859007 false 0001859007 2023-04-03
2023-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
April 3, 2023
ZYVERSA THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
001-41184 |
|
86-2685744 |
|
(State
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
|
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2200 N. Commerce Parkway,
Suite 208
Weston,
Florida,
33326
(Address
of principal executive offices) (Zip Code)
(754)
231-1688
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of Each Class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
ZVSA |
|
The Nasdaq Global Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
ZyVersa
Therapeutics, Inc. (the “Company”) issued a press release on April
3, 2023, disclosing financial information and operating metrics for
its fourth quarter and fiscal year ended December 31, 2022 and
discussing its business outlook. A copy of the Company’s press
release is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
Item
7.01. Regulation FD Disclosure.
See
“Item 2.02 Results of Operations and Financial Condition”
above.
The
information in this Current Report on Form 8-K under Items 2.02 and
7.01, including the information contained in Exhibit 99.1, is being
furnished to the Securities and Exchange Commission, and shall not
be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference into any filing under the
Securities Act of 1933 or the Exchange Act, except as shall be
expressly set forth by a specific reference in such
filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
April 3, 2023 |
|
|
| |
By: |
/s/
Stephen Glover |
| |
Name: |
Stephen
C. Glover |
| |
Title: |
Chief
Executive Officer |
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Aug 2023 to Sep 2023
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Sep 2022 to Sep 2023
